论文部分内容阅读
[目的]探讨青白栓对大鼠溃疡性结肠炎(UC)的治疗作用。[方法]采用二硝基氯苯和乙酸复合方法制备大鼠UC模型,经病理切片证实造模成功后,随机分为5组,青白栓高、中、低剂量组,模型组和柳氮磺吡啶栓组。各组大鼠根据其分组分别给予相应的处理20 d后,检测各组大鼠结肠组织中超氧化物歧化酶(SOD)、丙二醛(MDA)和血清白细胞介素2(IL-2)、白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)I、gAI、gM、体重及肠重指数的变化。[结果]青白栓高、中剂量组动物组织中SOD显著降低,MDA显著下降(P<0.01),青白栓高剂量组动物血清中IL-2I、L-6、TNF-α均显著降低(P<0.05,<0.01)。[结论]青白栓可有效地用于实验性UC的治疗。
[Objective] To investigate the therapeutic effect of Qingbai suppository on ulcerative colitis (UC) in rats. [Methods] Rat UC models were prepared by complex method of dinitrochlorobenzene and acetic acid. After successful modeling, confirmed by pathological section, they were randomly divided into 5 groups: Qingbai suppository high, middle and low dose groups, model group and sulfasalazine. Pyridine plug group. The rats in each group were given corresponding treatment according to their groups for 20 days. Then, the superoxide dismutase (SOD), malondialdehyde (MDA) and serum interleukin-2 (IL-2) in the colon tissue of each group were detected. Interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) I, gAI, gM, body weight, and intestinal weight index. [Results] The SOD was significantly decreased and the MDA was significantly decreased in the high- and medium-dose Qingbai Suppository groups (P<0.01). The serum IL-2I, L-6, and TNF-α were significantly decreased in the high-dose Qingbaisu group (P<0.01). <0.05, <0.01). [Conclusion] Qingbai suppository can be effectively used for the treatment of experimental UC.